A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
=== Regulatory status === This medication first reached market in 1973. It is approved in 21 countries worldwide, which does not include its home country of Denmark. It was taken off the approved list in India in 2014, citing a lack of required information such as mandatory clinical trial results in its 1998 approval decision. It is approved in China.
18 December: The Ministry of Education cancels Gloriavale Christian School's registration as a private school effective 23 January next year, citing insufficient evidence that the school was complying with registration criteria. Wellington High Court Justice Jason McHerron orders Corrections Department chief executive Jeremy Lightfoot to comply with a legal requirement entitling prisoners to at least one hour of exercise daily. The Waihi North extension of OceanaGold's Waihi mine becomes the first mining project to gain approval under the Fast-track Approvals Act 2024's regime. The Whangarei District Council votes unanimously to reject plans for fast-tracked sand mining at Bream Bay. 19 December: Esarona David Lologa is sentence to life imprisonment with a minimum term of 22 years for murdering five people and causing the Loafers Lodge fire in 2023. High Court Justice David Gendall rules that Justice Minister Paul Goldsmith unlawfully appointed Human Rights Commissioner Stephen Rainbow and Race Relations Commissioner Melissa Derby. 20 December — Members of the Brian Tamaki–aligned "True Patriots of NZ" attempt to block a Sikh rally in Auckland. Police intervene to keep the two groups apart. 22 December — India and New Zealand confirm plans to sign a free trade agreement in 2026. 23 December - A scrub fire destroys multiple buildings and forces the evacuation of several residents between Fernhill, Hawke's Bay and the Ngaruroro River bridge.
Therefore, in practice, a chiral method development laboratory settings, acts like a high-throughput screening protocol, of conducting a systematic screening of various CSP's by advanced column switching devices, trying automatically and systematically various mobile-phase combinations, effectively employing a trial-and-error strategy. Because of the highly complex retention mechanism of a chiral stationary-phase due to chiral recognition, whose principles have not been deciphered, it is often difficult, if not impossible to predict in advance the steps that can be successfully applied to the enantiomers at hand as part of method development. That's why the standard approach in the method development is high throughput screening, to evaluate or examine a series of stationary phases, using various mobile-phase combinations, to increase the chance of finding a suitable separation condition.
While there is limited literature on radiation injury to animals, there is no evidence of other types of radiation injury. Diagnostic radiation has been shown to cause local burns in animals, typically resulting from prolonged exposure of body parts or sparks from old x-ray tubes. It is important to note that the frequency of injury to veterinary staff and veterinarians is significantly lower than that in human medicine, highlighting the safety of diagnostic radiation in veterinary practice. In veterinary medicine, fewer images are taken compared to human medicine, particularly fewer CT scans. However, due to the manual restraint of animals to avoid anesthesia, at least one person is present in the control area, resulting in significantly higher radiation exposure than that of human medical staff. It is important to note that since the 1970s, dosimeters have been used to measure the radiation exposure of veterinary personnel, ensuring their safety. Feline hyperthyroidism (overactive thyroid) is a common disease in older cats. Radioiodine therapy is considered by many authors to be the treatment of choice. Following the administration of radioactive iodine, cats are kept in an isolation pen. The cat's radioactivity is measured to determine the time of discharge, which is typically 14 days after the start of therapy. The therapy requires significant radiation protection measures and is currently only offered at two veterinary facilities in Germany (as of 2010).
=== Common names === Vernacular names used for this species include black stone flower, stone lichen, sea lichen, kalpasi, kalpas, kalpashi, and kalpash. The latter name and its variations, however, have been used as a crude drug in Indian medicines for more than one species, including Parmotrema perlatum, Parmotrema tinctorum, and Everniastrum cirrhatum. In North America, vernacular names used for the species include "powdered ruffle lichen", "powdered scatter-rug", and "queen ruffle". The species epithet perlatum refers to the pearl-like margins of the lobes, which are directly referenced in Hudson's original 1762 description of the species. He proposed the English name "pearl lichen"; this name later morphed into "pearly parmelia" in some 19th-century British accounts of lichen flora.
Sources: en.wikipedia.org
== Legal status == Ketazolam is a List 3 drug under the Betäubungsmittelgesetz, like almost all benzodiazepines in Germany. Ketazolam is a List II drugs of the Opium Law in the Netherlands. Ketazolam is a Schedule IV drug under the Controlled Substances Act in the US.
30 August – The Electoral Commission submitted its Constituency Review Report 2023 to the Oireachtas. It recommended that the number of Teachtaí Dála be increased from 160 to 174, and that the number of Dáil constituencies be increased from 39 to 43. The increases take account of a population rise of 8% since 2016.
== L == Lamina A layer of neurons in a neural structure. In the spinal cord and cerebral cortex, laminae are functionally and anatomically distinct. Lateral geniculate nucleus (LGN) A relay center in the thalamus that receives input from the retina and sends visual information to the visual cortex. Lateral inhibition A neural mechanism in which an excited neuron reduces the activity of its neighbors. Enhances contrast in sensory systems such as vision and touch. Lateral sulcus A deep groove in the cerebral cortex that separates the frontal lobe and parietal lobe from the temporal lobe. Learning The acquisition of new knowledge or skills through experience, study, or teaching. In neuroscience, learning is linked to synaptic plasticity and neural circuit changes. Learning A neurobiological process through which experience induces lasting changes in the nervous system, leading to the acquisition or modification of behavior, knowledge, or skills. Lentiform nucleus A structure within the basal ganglia composed of the putamen and globus pallidus, involved in motor control and learning. Lesion Damage or abnormal change in brain tissue, caused by injury, stroke, disease, or surgery. Lesion studies are used to investigate brain function. Levodopa A precursor to dopamine used in the treatment of Parkinson’s disease. It crosses the blood–brain barrier and is converted to dopamine in the brain. Limbic system A group of interconnected brain structures involved in emotion, motivation, memory, and olfaction. Includes the amygdala, hippocampus, and cingulate cortex.
Such an organization requires the issuing of special laws by the governing state, since they are not covered by the normal administrative structure of the respective states. In 2010 only three Kommunalverbände besonderer Art exist.
==== Fatty acids ==== There has been a growing interest in the role of long-chain omega-3 polyunsaturated fatty acids to reduce inflammation and alleviate the symptoms of RA. Metabolism of omega-3 polyunsaturated fatty acids produces docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which inhibit pro-inflammatory eicosanoids and cytokines (TNF-a, IL-1b, and IL-6), decreasing both lymphocyte proliferation and reactive oxygen species. These studies showed evidence for significant clinical improvements on RA in inflammatory status and articular index. Gamma-linolenic acid, an omega-6 fatty acid, may reduce pain, tender joint count, and stiffness, and is generally safe. For omega-3 polyunsaturated fatty acids (found in fish oil, flax oil and hemp oil), a meta-analysis reported a favorable effect on pain, although confidence in the effect was considered moderate. The same review reported less inflammation but no difference in joint function. A review examined the effect of marine oil omega-3 fatty acids on pro-inflammatory eicosanoid concentrations; leukotriene4 (LTB4) was lowered in people with rheumatoid arthritis but not in those with non-autoimmune chronic diseases. Fish consumption has no association with RA. A fourth review limited inclusion to trials in which people eat ≥2.7 g/day for more than three months. The use of pain relief medication was decreased, but improvements in tender or swollen joints, morning stiffness, and physical function were unchanged.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.